Showing 1 - 5 results of 5 for search 'Josep Tabernero', query time: 0.02s Refine Results
  1. 1
    Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients.

    Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients. by Anita K Gandhi, Tao Shi, Mingyu Li, Ulf Jungnelius, Alfredo Romano, Josep Tabernero, Salvatore Siena, Peter H Schafer, Rajesh Chopra

    Published 2013-01-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer

    Pooled safety analysis of two phase 3 studies investigating trifluridine/tipiracil plus bevacizumab in patients with metastatic colorectal cancer by Julien Taieb, Marwan Fakih, Gabor Liposits, Gerald W. Prager, Eric Van Cutsem, Fortunato Ciardiello, Nadia Amellal, Elizabeth Calleja, Mei Liu, Lucas Roby, Josep Tabernero, Thierry André

    Published 2025-01-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

    Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical tr... by Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell

    Published 2024-03-01
    Get full text
    Article
    Save to List
    Saved in:
  4. 4
    A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers

    A phase Ia study of the MEK1/2 inhibitor PD-0325901 with the c-MET inhibitor crizotinib in patients with advanced solid cancers by Peter Gallagher, Christian Rolfo, Elena Elez, Julien Taieb, Jennifer Houlden, Linda Collins, Corran Roberts, Thierry André, Mark Lawler, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Vlad Popovici, Alberto Bardelli, Robbie Carson, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Bryan T. Hennessy, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

    Published 2025-03-01
    Get full text
    Article
    Save to List
    Saved in:
  5. 5
    A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC)

    A Phase Ia/b study of MEK1/2 inhibitor binimetinib with MET inhibitor crizotinib in patients with RAS mutant advanced colorectal cancer (MErCuRIC) by Francesca Aroldi, Elena Elez, Thierry André, Geraldine Perkins, Hans Prenen, Vlad Popovici, Peter Gallagher, Jennifer Houlden, Linda Collins, Corran Roberts, Christian Rolfo, Federica Di Nicolantonio, Margaret Grayson, Ruth Boyd, Karolien Bettens, Jurgen Delfavero, Victoria Coyle, Mark Lawler, Hajrah Khawaja, Pierre Laurent-Puig, Manuel Salto-Tellez, Tim S. Maughan, Josep Tabernero, Richard Adams, Robert Jones, Bryan T. Hennessy, Alberto Bardelli, Marc Peeters, Mark R. Middleton, Richard H. Wilson, Sandra Van Schaeybroeck, on behalf of the MErCuRIC Trial Consortium

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: